Latest Clinical Trials
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Washington University School of Medicine NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 FOLFIRINOX + RT for Pancreatic Cancer Massachusetts General Hospital NA
COMPLETED
(Sep 1, 2026)
PHASE2 Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Centre Oscar Lambret NA
TERMINATED
(Sep 1, 2026)
PHASE1, PHASE2 Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 RemeGen Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Cabozantinib in High Grade Neuroendocrine Neoplasms Washington University School of Medicine NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Institut du Cancer de Montpellier - Val d'Aurelle NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer Zhou Fuxiang NA
COMPLETED
(Sep 1, 2026)
PHASE2 Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. Amgen NA
TERMINATED
(Sep 1, 2026)
PHASE3 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Jazz Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease NRG Oncology NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer Boehringer Ingelheim NA
COMPLETED
(Sep 1, 2026)
PHASE1 Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma Fifth Affiliated Hospital, Sun Yat-Sen University NA
WITHDRAWN
(Sep 1, 2026)
PHASE2 Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE2 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Gilead Sciences NA
RECRUITING
(Sep 1, 2026)
PHASE3 Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma Sir Run Run Shaw Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial ECOG-ACRIN Cancer Research Group NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) DualityBio Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. BriaCell Therapeutics Corporation NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Memorial Sloan Kettering Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma AskGene Pharma, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
RECRUITING
(Sep 1, 2026)
PHASE2 Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Shandong Cancer Hospital and Institute NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease Gruppo Oncologico del Nord-Ovest NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Phase 1/1b Study of IAM1363 in HER2 Cancers Iambic Therapeutics, Inc NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Boehringer Ingelheim NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction Xijing Hospital NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) MediLink Therapeutics (Suzhou) Co., Ltd. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer Fudan University NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE3 Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE2 Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study Fudan University NA
RECRUITING
(Sep 1, 2026)
PHASE3 Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC Zhongnan Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. RemeGen Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE3 Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial Sun Yat-sen University NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE3 Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM Union Hospital, Tongji Medical College, Huazhong University of Science and Technology NA
RECRUITING
(Sep 1, 2026)
PHASE2 Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma University of Vermont Medical Center NA
ENROLLING BY INVITATION
(Sep 1, 2026)
PHASE2 A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma Nanjing Leads Biolabs Co.,Ltd NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Xuelei Ma MD NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases Peking University Cancer Hospital & Institute NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma Ono Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE3 A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Shanghai Henlius Biotech NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors Sunshine Lake Pharma Co., Ltd. NA
RECRUITING
(Sep 1, 2026)
PHASE1 Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer Tianjin Medical University Cancer Institute and Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Shanghai Zhongshan Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd Fujian Medical University NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer Fudan University NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
COMPLETED
(Aug 1, 2026)
PHASE3 MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer Medical College of Wisconsin NA
COMPLETED
(Aug 1, 2026)
PHASE2 Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Incyte Corporation NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC RenovoRx NA
RECRUITING
(Aug 1, 2026)
PHASE3 XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) Fudan University NA
COMPLETED
(Aug 1, 2026)
PHASE3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Merck Sharp & Dohme LLC NA
COMPLETED
(Aug 1, 2026)
PHASE3 Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer NRG Oncology NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer OHSU Knight Cancer Institute NA
COMPLETED
(Aug 1, 2026)
PHASE1 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab BeiGene NA
COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2 Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) AstraZeneca NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction Hoffmann-La Roche NA
COMPLETED
(Aug 1, 2026)
PHASE2 A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) Pfizer NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer Stanford University NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Lepu Biopharma Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial Alliance for Clinical Trials in Oncology NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 University of Nebraska NA
RECRUITING
(Aug 1, 2026)
PHASE2 Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature John Neoptolemos NA
RECRUITING
(Aug 1, 2026)
PHASE3 PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery Fudan University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) Seoul National University Hospital NA
RECRUITING
(Aug 1, 2026)
PHASE3 CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer Shanghai Changzheng Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response Alliance for Clinical Trials in Oncology NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors Beijing Biostar Pharmaceuticals Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial Jiangsu HengRui Medicine Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC Brown University NA
RECRUITING
(Aug 1, 2026)
PHASE2 Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Sun Yat-sen University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer Daiichi Sankyo NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases Biostar Pharma, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2 Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NRG Oncology NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Lepu Biopharma Co., Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Case Comprehensive Cancer Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer ALX Oncology Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer Astellas Pharma Global Development, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Merck Sharp & Dohme LLC NA
RECRUITING
(Aug 1, 2026)
PHASE3 NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer Women's Cancer Study Group GmbH NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Kristina A. Fanucci NA
RECRUITING
(Aug 1, 2026)
PHASE2 ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer Jennifer Dorth NA
RECRUITING
(Aug 1, 2026)
PHASE2 Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer University of Arkansas NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States BeOne Medicines NA
RECRUITING
(Aug 1, 2026)
PHASE2 Capecitabine in ER+/HER2-negative Breast Cancer University Health Network, Toronto NA
RECRUITING
(Aug 1, 2026)
PHASE2 Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer Shandong Cancer Hospital and Institute NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Medical University of South Carolina NA
RECRUITING
(Aug 1, 2026)
PHASE2 Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma Fudan University NA
RECRUITING
(Aug 1, 2026)
PHASE2 Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer Fujian Cancer Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma Corbus Pharmaceuticals Inc. NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial Sun Yat-sen University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer Zhejiang University NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM) Dai, Guanghai NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal Wang Xin NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer Shanghai Changzheng Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Tianjin Medical University Cancer Institute and Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Xijing Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). Astellas Pharma Global Development, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer University Hospital, Bordeaux NA
COMPLETED
(Jul 1, 2026)
PHASE3 Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial National Cancer Institute (NCI) NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer Centre Hospitalier Universitaire Dijon NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Laura M. Spring, MD NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Ultra-fractionated Radiotherapy for Rectal Cancer University of Texas Southwestern Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Colette Shen NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) Merck Sharp & Dohme LLC NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer Hoffmann-La Roche NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence Institute of Oncology Ljubljana NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Shanghai Junshi Bioscience Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Amgen NA
TERMINATED
(Jul 1, 2026)
PHASE1, PHASE2 Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) EMD Serono Research & Development Institute, Inc. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer UNICANCER NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 TIME in Immunotherapy Combined With nCRT for Rectal Cancer Peking Union Medical College Hospital NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer BeiGene NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Galunisertib Combined With Capecitabine in Advanced CRC With PM The Netherlands Cancer Institute NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer State University of New York - Downstate Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer AstraZeneca NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Sun Yat-sen University NA
COMPLETED
(Jul 1, 2026)
PHASE2 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer InnoPharmax Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Bristol-Myers Squibb NA
RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement Affiliated Cancer Hospital of Shantou University Medical College NA
RECRUITING
(Jul 1, 2026)
PHASE2 Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
RECRUITING
(Jul 1, 2026)
PHASE2 Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC Hebei Medical University Fourth Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors Tianjin Medical University Cancer Institute and Hospital NA
WITHDRAWN
(Jul 1, 2026)
PHASE2 Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer Shanghai Changzheng Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) Sichuan Baili Pharmaceutical Co., Ltd. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer Immunomic Therapeutics, Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE1 Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Guangdong Provincial People's Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma Chinese University of Hong Kong NA
RECRUITING
(Jul 1, 2026)
PHASE2 Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer Fujian Cancer Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer Zhejiang Cancer Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma Sun Yat-sen University NA
RECRUITING
(Jul 1, 2026)
PHASE3 Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma Tang-Du Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Midhun Malla NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer Lepu Biopharma Co., Ltd. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. Xijing Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer Fudan University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer University of Southern California NA
COMPLETED
(Jun 1, 2026)
PHASE2 Phase I Platinum Based Chemotherapy Plus Indomethacin UMC Utrecht NA
COMPLETED
(Jun 1, 2026)
PHASE1 Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer Massachusetts General Hospital NA
COMPLETED
(Jun 1, 2026)
PHASE2 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Eli Lilly and Company NA
COMPLETED
(Jun 1, 2026)
PHASE1 Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? University of Birmingham NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 CapTemY90 for Grade 2/3 NET Liver Metastases Abramson Cancer Center at Penn Medicine NA
RECRUITING
(Jun 1, 2026)
PHASE2 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer H. Lee Moffitt Cancer Center and Research Institute NA
COMPLETED
(Jun 1, 2026)
PHASE1 A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors Akeso NA
COMPLETED
(Jun 1, 2026)
PHASE1, PHASE2 A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) AstraZeneca NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer National Cancer Institute (NCI) NA
SUSPENDED
(Jun 1, 2026)
PHASE1 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers National Cancer Institute (NCI) NA
RECRUITING
(Jun 1, 2026)
PHASE1 A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 Genentech, Inc. NA
COMPLETED
(Jun 1, 2026)
PHASE1 Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients National Cancer Centre, Singapore NA
RECRUITING
(Jun 1, 2026)
PHASE2 Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Centre Leon Berard NA
RECRUITING
(Jun 1, 2026)
PHASE3 Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer Sir Run Run Shaw Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) Stanford University NA
RECRUITING
(Jun 1, 2026)
PHASE2 Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Jun 1, 2026)
PHASE2 Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Jun 1, 2026)
PHASE2 Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer Hebei Medical University Fourth Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） Hebei Medical University Fourth Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) Hebei Medical University Fourth Hospital NA
SUSPENDED
(Jun 1, 2026)
PHASE2 A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor Jiangsu HengRui Medicine Co., Ltd. NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer Erasmus Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE3 Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma Kai Hu NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis Ruijin Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Jun 1, 2026)
PHASE3 Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations Fudan University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Jun 1, 2026)
PHASE2 Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer Chen Lizhu NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study Fujian Medical University NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. Ming Liu NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study Harbin Medical University NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma Kaohsiung Medical University Chung-Ho Memorial Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine Seoul National University Bundang Hospital NA
ENROLLING BY INVITATION
(Jun 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer Beijing Biostar Pharmaceuticals Co., Ltd. NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zhifeng Zhao, PhD NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation Harbin Medical University NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Jun 1, 2026)
PHASE2 Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer Tianjin Medical University Cancer Institute and Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Akeso NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project) Vall d'Hebron Institute of Oncology NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Lenvatinib Plus Chemotherapy for pNET Liver Metastases Peking Union Medical College Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) Sun Yat-sen University NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer The Netherlands Cancer Institute NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients Sun Yat-sen University NA
COMPLETED
(May 1, 2026)
PHASE3 Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Northwell Health NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of the Impact of DPD Activity on the Efficacy of Capecitabine Centre Antoine Lacassagne NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) Fudan University NA
COMPLETED
(May 1, 2026)
PHASE2 TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Borstkanker Onderzoek Groep NA
COMPLETED
(May 1, 2026)
PHASE2 PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy Asan Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC AstraZeneca NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. Gruppo Oncologico del Nord-Ovest NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Pfizer NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer Centre Hospitalier Universitaire Vaudois NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas University of California, Irvine NA
RECRUITING
(May 1, 2026)
PHASE1 Radioembolization in Elderly/ Fragile Patients With mCRC UMC Utrecht NA
TERMINATED
(May 1, 2026)
PHASE2 Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma Sun Yat-sen University NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB315 in Patients With Advanced Solid Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE1 A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) AstraZeneca NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body Arcus Biosciences, Inc. NA
COMPLETED
(May 1, 2026)
PHASE3 A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer Taizhou Hanzhong biomedical co. LTD NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 A Study of Tucatinib and Trastuzumab in People With Rectal Cancer Memorial Sloan Kettering Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma AstraZeneca NA
RECRUITING
(May 1, 2026)
PHASE2 Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma Jiangxi Provincial Cancer Hospital NA
RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer Mayo Clinic NA
RECRUITING
(May 1, 2026)
PHASE2 A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer GlaxoSmithKline NA
RECRUITING
(May 1, 2026)
PHASE2 Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos NA
RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease Delcath Systems Inc. NA
RECRUITING
(May 1, 2026)
PHASE2 TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] Nanjing Leads Biolabs Co.,Ltd NA
RECRUITING
(May 1, 2026)
PHASE2 Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. NA
RECRUITING
(May 1, 2026)
PHASE3 A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer Jiangsu Cancer Institute & Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer Sun Yat-sen University NA
RECRUITING
(May 1, 2026)
PHASE2 Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Mayo Clinic NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer Chinese PLA General Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma NingBo Junyan Hongshi Biosciences Co., Ltd NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Adjuvant Trial in Pancreatic Neuroendocrine Tumors Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial Tianjin Medical University Cancer Institute and Hospital NA
RECRUITING
(May 1, 2026)
PHASE2 Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC Beijing Friendship Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2, PHASE3 SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer Gustave Roussy, Cancer Campus, Grand Paris NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance Jiangsu Cancer Institute & Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma The First Affiliated Hospital of Henan University of Science and Technology NA
RECRUITING
(May 1, 2026)
PHASE2 Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery Tianjin Medical University Cancer Institute and Hospital NA
RECRUITING
(May 1, 2026)
PHASE3 Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(May 1, 2026)
PHASE3 QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ Qilu Pharmaceutical Co., Ltd. NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer Centre Antoine Lacassagne NA
COMPLETED
(Apr 1, 2026)
PHASE1 Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial University Medical Center Groningen NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Providence Health & Services NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer Providence Health & Services NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer M.D. Anderson Cancer Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer National Cancer Center, Korea NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis National Cancer Institute (NCI) NA
TERMINATED
(Apr 1, 2026)
PHASE2 A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC Asan Medical Center NA
COMPLETED
(Apr 1, 2026)
PHASE2 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer GBG Forschungs GmbH NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Merck Sharp & Dohme LLC NA
COMPLETED
(Apr 1, 2026)
PHASE3 Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma National Cancer Center Hospital East NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer Asan Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma Hoffmann-La Roche NA
TERMINATED
(Apr 1, 2026)
PHASE1, PHASE2 Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy National Cancer Center Hospital East NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma National Cancer Centre, Singapore NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) Sichuan Baili Pharmaceutical Co., Ltd. NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3 Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer Jinhua Central Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis Washington University School of Medicine NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer Pei-Rong Ding NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer SUNHO（China）BioPharmaceutical CO., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Marker Therapeutics, Inc. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Apr 1, 2026)
PHASE2 Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Apr 1, 2026)
PHASE2 Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. Sun Yat-sen University NA
RECRUITING
(Apr 1, 2026)
PHASE2 Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC Sun Yat-sen University NA
RECRUITING
(Apr 1, 2026)
PHASE3 Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy National Cancer Institute, Naples NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. Hansoh BioMedical R&D Company NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Antengene Biologics Limited NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] Nanjing Leads Biolabs Co.,Ltd NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma Sun Yat-sen University NA
RECRUITING
(Apr 1, 2026)
PHASE2 LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer Daping Hospital and the Research Institute of Surgery of the Third Military Medical University NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer MedSIR NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 JS212 Combination Therapies in Metastatic Colorectal Cancer Shanghai Junshi Bioscience Co., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2 Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer Guangdong Provincial People's Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer Chinese PLA General Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer Sun Yat-sen University NA
RECRUITING
(Apr 1, 2026)
PHASE3 Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma National Cancer Center Hospital East NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer Chongqing University Cancer Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study Sun Yat-sen University NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer Fudan University NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors BOE Technology Group Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer Mabwell (Shanghai) Bioscience Co., Ltd. NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer Fudan University NA
RECRUITING
(Apr 1, 2026)
PHASE2 Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer Fudan University NA
RECRUITING
(Apr 1, 2026)
PHASE2 Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases Tianjin Medical University Cancer Institute and Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease National University Hospital, Singapore NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer Xijing Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer. Centre Oscar Lambret NA
COMPLETED
(Mar 1, 2026)
PHASE2 Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) Institut de Cancérologie de Lorraine NA
COMPLETED
(Mar 1, 2026)
PHASE2 Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Koen Rovers NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2, PHASE3 Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer Vejle Hospital NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) University of Southern California NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 A Study of DB-1310 in Advanced/Metastatic Solid Tumors DualityBio Inc. NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Fudan University NA
RECRUITING
(Mar 1, 2026)
PHASE3 Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response Sun Yat-sen University NA
RECRUITING
(Mar 1, 2026)
PHASE3 LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis Daping Hospital and the Research Institute of Surgery of the Third Military Medical University NA
RECRUITING
(Mar 1, 2026)
PHASE1 The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis Cancer Institute and Hospital, Chinese Academy of Medical Sciences NA
RECRUITING
(Mar 1, 2026)
PHASE2 Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma Sun Yat-sen University NA
RECRUITING
(Mar 1, 2026)
PHASE2 Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer Seventh Medical Center of PLA General Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE2 Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea Tianjin Medical University Cancer Institute and Hospital NA
COMPLETED
(Mar 1, 2026)
PHASE2 Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment Fujian Cancer Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE3 Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma. Fudan University NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer Fujian Cancer Hospital NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer J. W. A. Burger NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy The Netherlands Cancer Institute NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance Union Hospital, Tongji Medical College, Huazhong University of Science and Technology NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma Fudan University NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial Fudan University NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 
